Enrolling Clinical Trials: Rucaparib for the Treatment of Pancreatic Cancer - Penn Medicine
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration | Journal of Clinical Oncology
![PDF] Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/52c115c5bf799368014e6b136b39cae306751b37/3-Figure1-1.png "PDF] Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer | Semantic Scholar")
PDF] Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer | Semantic Scholar
Rucaparib Approved as Maintenance Therapy for Ovarian Cancer - NCI
Rucaparib Shows Clinical Benefit as Maintenance Therapy in Patients with Recurrent Ovarian Cancer | ESMO
Rucaparib – second PARP inhibitor hits the market for ovarian cancer | MDedge Hematology and Oncology
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo- controlled, phase 3 trial - The Lancet
National Ovarian Cancer Coalition on Twitter: "Breaking: Clovis Oncology's Rucaparib Significantly Improved Progression-Free Survival in OVC Populations #ARIEL3 https://t.co/vmCpVOl9PZ https://t.co/YK1769oREU" / Twitter
The PARP Inhibitor Rucaparib in the Maintenance Therapy of Recurrent Ovarian Carcinoma: Highlights from the ARIEL3 Clinical Trial
The PARP Inhibitor Rucaparib in the Maintenance Therapy of Recurrent Ovarian Carcinoma: Highlights from the ARIEL3 Clinical Trial
Table 4 from Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy | Semantic Scholar
FDA Approves Olaparib, Rucaparib to Treat Prostate Cancer - NCI
Rucaparib: the past, present, and future of a newly approved PARP inhi | OTT
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS) | BMC Cancer | Full Text
Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian | DDDT
Clovis Oncology Announces Availability of Rubraca®▽ (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Germany | Business Wire
Rucaparib | ≥99%(HPLC) | Selleck | PARP inhibitor
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo- controlled, phase 3 trial - The Lancet
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events | International Journal of Gynecologic Cancer
The kinase polypharmacology landscape of clinical PARP inhibitors | Scientific Reports
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial - The Lancet Oncology
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo- controlled, phase 3 trial - The Lancet
Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer. - Abstract - Europe PMC
Rucaparib: the past, present, and future of a newly approved PARP inhi | OTT
PARP Inhibitors: Where Are We in 2020 and What's Coming Next?
